New Immune-Boosting drug tested to shrink rectal tumors before surgery
NCT ID NCT04130854
Summary
This study is testing if adding an experimental immunotherapy drug (APX005M) to standard radiation and chemotherapy before surgery helps shrink rectal tumors more effectively. It will involve 58 adults with locally advanced rectal cancer who have not had prior treatment. The main goal is to see if the combination leads to a complete disappearance of cancer cells in the surgically removed tissue.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED RECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Oregon Health & Science University
Portland, Oregon, 97239, United States
-
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
Dallas, Texas, 75390, United States
-
The University of Arizona Cancer Center
Tucson, Arizona, 85724, United States
-
Wake Forest Baptist Health Sciences
Winston-Salem, North Carolina, 27157, United States
Conditions
Explore the condition pages connected to this study.